Tirzepatide, like all GLP-1 and GIP agonists, carries well-documented side effects including nausea, vomiting, constipation, and reduced appetite in the first 14 weeks of treatment
"Allow all cookies" cookie "Decline all cookies" cookie Customer-specific caching These cookies are used to make the shopping experience even more appealing, for example for the recognition of the visitor
Its low molecular weight (~340 Da) means it reaches tissue compartments that larger peptides may not, and its stability profile is well-suited to combination formulations
Remodeling classification system considering left ventricular volume in patients with aortic valve stenosis: Association with adverse cardiovascular outcomes
Who should not use peptides
Your healthcare provider will have to submit documentation to Aetna for prior authorization of GLP-1 medications for weight loss that demonstrates that you meet certain criteria, including body mass index (BMI), weight-related health conditions, and prior treatment history
